Preparations for the Assessment of COVID-19 Infection and Long-Term Cardiovascular Risk

Jaehun Jung1,2

  • 1Artificial Intelligence and Big-Data Convergence Center, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea.

Insights

Long-COVID may increase cardiovascular risk, but its long-term effects require further study. South Korea is establishing a large cohort to gather real-world evidence on post-COVID conditions.

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Public Health

Background:

  • Growing evidence links coronavirus disease 2019 (COVID-19) to increased cardiovascular disease (CVD) risk.
  • The duration and magnitude of long-term cardiovascular risk following COVID-19 infection remain incompletely understood.
  • Distinguishing acute complications from post-acute cardiovascular manifestations of COVID-19 is challenging, complicating the definition of Long-COVID.

Purpose of the Study:

  • To establish a prospective cohort of COVID-19 survivors to investigate the long-term cardiovascular impact.
  • To link COVID-19 cases with national health insurance data for comprehensive real-world evidence generation.
  • To address the need for robust data on the long-term effects of SARS-CoV-2 infection, including potential Long-COVID conditions.

Main Methods:

  • Establishment of a prospective cohort comprising 10,000 confirmed COVID-19 cases.
  • Linking the COVID-19 cohort with claims data from the National Health Insurance Service (NHIS).
  • Utilizing a new platform developed by the Korean government and KDCA for long-term impact assessment.

Main Results:

  • The study is designed to accumulate significant real-world evidence on the long-term consequences of COVID-19.
  • The cohort linkage aims to provide insights into the cardiovascular risks associated with COVID-19.
  • Data will help clarify the prevalence and characteristics of post-acute COVID-19 conditions.

Conclusions:

  • A robust prospective cohort linked to national claims data will enhance understanding of Long-COVID.
  • This initiative is expected to yield critical real-world evidence on the long-term cardiovascular health of COVID-19 survivors.
  • The findings will inform public health strategies and clinical management of post-COVID conditions.

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
31
Assessment of the Cardiovascular System I: Subjective Data01:23

Assessment of the Cardiovascular System I: Subjective Data

A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
422
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
22
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
22
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
46
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
19